Celsius Therapeutics has launched with a $65m series A financing. Celsius was co-founded by Aviv Regev, Ph.D., core institute member, chair of the faculty and director of the Klarman Cell Observatory at the Broad Institute of MIT and Harvard, Professor of Biology at MIT and an investigator at the Howard Hughes Medical Institute. The start-up will combine single-cell genomics with machine learning algorithms to pinpoint specific cells that influence disease and identify the gene that triggers the fault. “Genomics is revolutionising medicine by providing unprecedented insights into how our bodies work,” said Dr. David Sinclair, CEO of Genomic Therapeutics. The financing was led by Third Rock Ventures, with participation from GV, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and others.
Celsius Therapeutics has launched with a $65m series A financing. The start-up will combine single-cell genomics with machine learning algorithms to pinpoint specific cells that influence disease and identify the gene that triggers the fault. “Genomics is revolutionising medicine by providing unprecedented insights into how our bodies work,” said Dr. David Sinclair, CEO of Genomic Therapeutics. The financing was led by Third Rock Ventures, with participation from GV, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and others.